Declared Dividend • May 31
Dividend increased to €1.40 Dividend of €1.40 is 12% higher than last year. Ex-date: 1st July 2026 Payment date: 3rd July 2026 Dividend yield will be 3.6%, which is higher than the industry average of 0.9%. Sustainability & Growth The dividend has increased by an average of 7.6% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 45% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • May 20
Equasens Société anonyme, Annual General Meeting, Jun 25, 2026 Equasens Société anonyme, Annual General Meeting, Jun 25, 2026. Location: 05 allee de saint cloud, villers les nancy France Valuation Update With 7 Day Price Move • Mar 31
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to €40.10, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 15x in the Healthcare Services industry in Europe. Total loss to shareholders of 39% over the past three years. Announcement • Mar 30
Equasens Société Anonyme Proposes the Payment of A Gross Dividend for the Year Ended 31 December 2025 Equasens Société anonyme propose the payment of a gross dividend of €1.40 per share for Fiscal Year 2025, subject to approval by the General Meeting on June 25, 2026. Price Target Changed • Jan 05
Price target decreased by 7.6% to €55.74 Down from €60.30, the current price target is an average from 5 analysts. New target price is 33% above last closing price of €41.90. Stock is down 5.0% over the past year. The company is forecast to post earnings per share of €2.46 for next year compared to €2.41 last year. Announcement • Nov 08
Equasens Société Anonyme Provides Earnings Guidance for the Year 2025 Equasens Société anonyme provided earnings guidance for the year 2025. The Group maintains its guidance for revenue growth of nearly 10% on a reported basis in the second half of 2025. The Group remains on the lookout for external growth opportunities, in particular to round out its service offering, strengthen its distribution networks, and support its continued expansion in Europe. Reported Earnings • Oct 01
First half 2025 earnings released: EPS: €1.14 (vs €1.13 in 1H 2024) First half 2025 results: EPS: €1.14 (up from €1.13 in 1H 2024). Revenue: €116.0m (up 7.4% from 1H 2024). Net income: €17.3m (flat on 1H 2024). Profit margin: 15% (down from 16% in 1H 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 14% per year, which means it is performing significantly worse than earnings. Upcoming Dividend • Jun 25
Upcoming dividend of €1.25 per share Eligible shareholders must have bought the stock before 02 July 2025. Payment date: 04 July 2025. Payout ratio is a comfortable 52% and this is well supported by cash flows. Trailing yield: 2.5%. Lower than top quartile of French dividend payers (5.4%). Higher than average of industry peers (1.2%). Declared Dividend • May 19
Dividend of €1.25 announced Dividend of €1.25 is the same as last year. Ex-date: 2nd July 2025 Payment date: 4th July 2025 Dividend yield will be 2.6%, which is higher than the industry average of 0.9%. Sustainability & Growth The dividend has increased by an average of 9.6% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 30% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Valuation Update With 7 Day Price Move • May 13
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to €47.50, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 17x in the Healthcare Services industry in Europe. Total loss to shareholders of 37% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €76.07 per share. Announcement • Apr 03
Equasens Société anonyme, Annual General Meeting, Jun 25, 2025 Equasens Société anonyme, Annual General Meeting, Jun 25, 2025. Major Estimate Revision • Mar 31
Consensus EPS estimates fall by 12% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from €237.9m to €232.5m. EPS estimate also fell from €3.00 per share to €2.63 per share. Net income forecast to shrink 7.3% next year vs 34% growth forecast for Healthcare Services industry in France . Consensus price target broadly unchanged at €57.98. Share price fell 7.5% to €32.65 over the past week. Announcement • Mar 30
Equasens Société anonyme Proposes the Payment of A Gross Dividend for the Year Ended 31 December 2024 Equasens Société anonyme proposed the payment of a gross dividend of €1.25 per share for the year ended 31 December 2024 at the Annual General Meeting on June 25, 2025. Announcement • Mar 29
Equasens Société anonyme Provides Earnings Guidance for the Year 2025 Equasens Société anonyme provided earnings guidance for the year 2025. Backed by investments in R&D, infrastructure and human capital both in France and in Europe, the Group maintains its target of a return to revenue growth in 2025, with positive momentum in first half followed by a marked acceleration in second half, with anticipated nominal growth of close to 10%. While profitability remains solid, it will continue to be impacted by the ongoing investments to prepare for this growth trajectory, which will be based on the Group's ability to deliver innovative, value-creating offerings to its customers. Price Target Changed • Oct 18
Price target decreased by 7.7% to €64.22 Down from €69.60, the current price target is an average from 6 analysts. New target price is 23% above last closing price of €52.00. Stock is down 19% over the past year. The company is forecast to post earnings per share of €2.99 for next year compared to €3.13 last year. Announcement • Sep 29
Equasens Société Anonyme Maintains Revenue Forecast for the Year 2024 Equasens Société anonyme announced that the Group maintained its forecast for a return to revenue growth starting in the second half of 2024, and an acceleration in 2025 driven by current investments and an economic climate that looks set to improve, particularly for pharmacies in France. Declared Dividend • Jun 21
Dividend increased to €1.25 Dividend of €1.25 is 8.7% higher than last year. Ex-date: 2nd July 2024 Payment date: 4th July 2024 Dividend yield will be 2.3%, which is higher than the industry average of 0.9%. Sustainability & Growth Dividend is well covered by both earnings (40% earnings payout ratio) and cash flows (48% cash payout ratio). The dividend has increased by an average of 9.6% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 25% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Valuation Update With 7 Day Price Move • Jun 18
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to €55.90, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 18x in the Healthcare Services industry in Europe. Total loss to shareholders of 37% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €83.68 per share. Buy Or Sell Opportunity • May 31
Now 21% undervalued Over the last 90 days, the stock has risen 33% to €62.70. The fair value is estimated to be €79.39, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 19%. For the next 3 years, revenue is forecast to grow by 3.6% per annum. Earnings are also forecast to grow by 5.0% per annum over the same time period. Valuation Update With 7 Day Price Move • Apr 05
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €59.40, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 18x in the Healthcare Services industry in Europe. Total loss to shareholders of 37% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €64.35 per share. Price Target Changed • Feb 08
Price target decreased by 9.0% to €71.55 Down from €78.65, the current price target is an average from 6 analysts. New target price is 48% above last closing price of €48.30. Stock is down 38% over the past year. The company is forecast to post earnings per share of €3.07 for next year compared to €3.08 last year. Buy Or Sell Opportunity • Feb 08
Now 23% undervalued after recent price drop Over the last 90 days, the stock has fallen 30% to €48.30. The fair value is estimated to be €62.80, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 19%. Revenue is forecast to grow by 6.9% in 2 years. Earnings are forecast to grow by 2.7% in the next 2 years. Announcement • Feb 07
Equasens Société anonyme to Report Fiscal Year 2023 Results on Mar 29, 2024 Equasens Société anonyme announced that they will report fiscal year 2023 results on Mar 29, 2024 New Risk • Jan 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Announcement • Dec 28
Equasens Group Announces Management Appointments, Effective 1 January 2024 Equasens Group announced a change in its Executive Committee with effect from 1 January 2024. Damien VALICONbecomes the new head of the Pharmagest Division: Damien VALICON, currently manager of the Medical Solutions Division, will now head up the Pharmagest Division. In this new role, he will be responsible for maintaining the commercial momentum of Pharmacie France and ASCA, supporting the growth of European subsidiaries (PHARMAGEST Belgium, PHARMAGEST Luxembourg, PHARMAGEST Italia and the recently created PHARMAGEST Germany), as well as the development of compliance solutions with MULTIMEDS and iMEDS, and the new ATOOPHARM e-learning business. Dominique GOURSAUDis appointed as head of the Medical Solutions Division: Dominique GOURSAUD, currently Chief Strategy and Business Development Officer, will now head up the Medical Solutions Division. In this new capacity, he will continue to strengthen the Division's sales organization and develop its service offering. Noëlle STOULIG is appointed as the new head of Communications for the Equasens Group: Noëlle STOULIG, currently European Marketing Manager for the Pharmagest Division, is appointed Director of Communications for Equasens Group. In this capacity, she will be responsible for spearheading the Group's global communications and brand strategy, both internally and externally. The missions of Grégoire DE ROTALIER, Deputy Chief Executive Officer and Manager of the Axigate Link Division, Nicolas LAFON, Manager of the Fintech Division, Franck FAVIER, Manager of the e-Connect Division, Frédérique SCHMIDT, Chief Financial Officer, and Sabrina GHARBI, Chief Human Resources Officer, remain unchanged. Announcement • Nov 24
Equasens Société anonyme (ENXTPA:EQS) and ARZ Haan AG acquired Ad Apotheken Datenverarbeitung Gmbh & Co. Kg. Equasens Société anonyme (ENXTPA:EQS) and ARZ Haan AG acquired Ad Apotheken Datenverarbeitung Gmbh & Co. Kg on November 23, 2023.Equasens Société anonyme (ENXTPA:EQS) and ARZ Haan AG completed the acquisition of Ad Apotheken Datenverarbeitung Gmbh & Co. Kg on November 23, 2023. New Risk • Nov 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Price Target Changed • Nov 13
Price target decreased by 9.5% to €85.18 Down from €94.12, the current price target is an average from 5 analysts. New target price is 51% above last closing price of €56.50. Stock is down 27% over the past year. The company is forecast to post earnings per share of €3.11 for next year compared to €3.08 last year. Valuation Update With 7 Day Price Move • Nov 10
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to €56.40, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 18x in the Healthcare Services industry in Europe. Total loss to shareholders of 34% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €57.95 per share. Reported Earnings • Oct 06
First half 2023 earnings released: EPS: €1.46 (vs €1.32 in 1H 2022) First half 2023 results: EPS: €1.46 (up from €1.32 in 1H 2022). Revenue: €112.6m (up 8.7% from 1H 2022). Net income: €22.0m (up 11% from 1H 2022). Profit margin: 20% (in line with 1H 2022). Revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 7.6% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Announcement • Aug 04
Equasens Société anonyme to Report Q3, 2023 Results on Nov 09, 2023 Equasens Société anonyme announced that they will report Q3, 2023 results at 5:40 PM, Central European Standard Time on Nov 09, 2023 Upcoming Dividend • Jun 26
Upcoming dividend of €1.15 per share at 1.3% yield Eligible shareholders must have bought the stock before 03 July 2023. Payment date: 05 July 2023. Trailing yield: 1.3%. Lower than top quartile of French dividend payers (5.2%). In line with average of industry peers (1.3%). Announcement • May 12
Equasens Société anonyme to Report First Half, 2023 Results on Sep 29, 2023 Equasens Société anonyme announced that they will report first half, 2023 results on Sep 29, 2023 Announcement • Feb 04
Equasens Société anonyme to Report Fiscal Year 2022 Results on Mar 24, 2023 Equasens Société anonyme announced that they will report fiscal year 2022 results After-Market on Mar 24, 2023 Announcement • Jan 20
Equasens Group Announces Executive Changes Equasens Group announced the appointment of Frédérique SCHMIDT as the Group's Chief Administrative and Financial Officer. She assumed her functions on 1 January 2023 and became a member of the Group Executive Committee. Frédérique SCHMIDT brings to the Group a solid track record of making use of the financial expertise she has acquired in international industrial groups to support strategy, operating activities and organisations. She succeeds Jean-Yves SAMSON, who is retiring after more than 30 years with the Group, first as Director of Management Control and then as Chief Administrative and Financial Officer. Board Change • Nov 16
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 3 experienced directors. 8 highly experienced directors. 3 independent directors (9 non-independent directors). Independent Director Celine Gris was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Sep 28
Investor sentiment deteriorated over the past week After last week's 16% share price decline to €61.40, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 28x in the Healthcare Services industry in Europe. Total returns to shareholders of 13% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €105 per share. Major Estimate Revision • Sep 24
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 EPS estimate increased from €2.88 to €3.50. Revenue forecast unchanged at €214.7m. Net income forecast to grow 26% next year vs 23% growth forecast for Healthcare Services industry in France. Consensus price target down from €111 to €105. Share price fell 4.5% to €69.30 over the past week. Price Target Changed • Sep 23
Price target decreased to €105 Down from €116, the current price target is an average from 3 analysts. New target price is 52% above last closing price of €69.30. Stock is down 29% over the past year. The company is forecast to post earnings per share of €2.88 for next year compared to €2.60 last year. Buying Opportunity • Sep 13
Now 22% undervalued Over the last 90 days, the stock is up 5.5%. The fair value is estimated to be €99.80, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.3% over the last 3 years. Earnings per share has grown by 14%. For the next 3 years, revenue is forecast to grow by 9.4% per annum. Earnings is also forecast to grow by 0.9% per annum over the same time period. Buying Opportunity • Aug 26
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 3.2%. The fair value is estimated to be €102, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.3% over the last 3 years. Earnings per share has grown by 14%. For the next 3 years, revenue is forecast to grow by 9.4% per annum. Earnings is also forecast to grow by 0.9% per annum over the same time period. Buying Opportunity • Aug 05
Now 22% undervalued Over the last 90 days, the stock is up 3.6%. The fair value is estimated to be €103, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.3% over the last 3 years. Earnings per share has grown by 14%. For the next 3 years, revenue is forecast to grow by 9.4% per annum. Earnings is also forecast to grow by 1.3% per annum over the same time period. Buying Opportunity • Jul 14
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 10%. The fair value is estimated to be €99.25, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.3% over the last 3 years. Earnings per share has grown by 14%. For the next 3 years, revenue is forecast to grow by 9.4% per annum. Earnings is also forecast to grow by 1.3% per annum over the same time period. Buying Opportunity • Jun 30
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 13%. The fair value is estimated to be €95.35, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.3% over the last 3 years. Earnings per share has grown by 14%. For the next 3 years, revenue is forecast to grow by 9.4% per annum. Earnings is also forecast to grow by 1.3% per annum over the same time period. Upcoming Dividend • Jun 23
Upcoming dividend of €1.05 per share Eligible shareholders must have bought the stock before 30 June 2022. Payment date: 04 July 2022. Payout ratio is a comfortable 40% and this is well supported by cash flows. Trailing yield: 1.4%. Lower than top quartile of French dividend payers (5.4%). In line with average of industry peers (1.4%). Buying Opportunity • Jun 13
Now 21% undervalued The stock has been flat over the last 90 days. The fair value is estimated to be €96.19, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.3% over the last 3 years. Earnings per share has grown by 14%. For the next 3 years, revenue is forecast to grow by 9.4% per annum. Earnings is also forecast to grow by 1.3% per annum over the same time period. Price Target Changed • May 20
Price target decreased to €119 Down from €129, the current price target is an average from 3 analysts. New target price is 47% above last closing price of €80.70. Stock is down 12% over the past year. The company is forecast to post earnings per share of €2.43 for next year compared to €2.04 last year. Price Target Changed • May 07
Price target decreased to €126 Down from €136, the current price target is an average from 3 analysts. New target price is 61% above last closing price of €78.40. Stock is down 16% over the past year. The company is forecast to post earnings per share of €2.43 for next year compared to €2.04 last year. Board Change • Apr 27
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 2 experienced directors. 7 highly experienced directors. 2 independent directors (8 non-independent directors). Independent Director Celine Gris was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Buying Opportunity • Feb 08
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 23%. The fair value is estimated to be €99.74, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.7% per annum over the last 3 years. Earnings per share has grown by 10% per annum over the last 3 years. Buying Opportunity • Jan 24
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 19%. The fair value is estimated to be €98.79, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.7% per annum over the last 3 years. Earnings per share has grown by 10% per annum over the last 3 years. 
